* patient with non-active graft * any significant side effect with previous covid-19 vaccination * within 28 days of bnt162b2 vaccine completion * already received more than and equal to three doses of covid-19 vaccination * previously received covid-19 vaccine other than bnt162b2 vaccine * previously received monoclonal antibody treatment that are specifically directed against the spike protein for severe acute respiratory syndrome (sars) coronavirus 2 (cov)-2 such as mab, bamlanivimab, etesevimab, casirivimab, imdevimab, sotrovimab and/or any combination. * thrombocytopenia (if less than 50,000 per microliter 30 days prior vaccination) * history of capillary leak syndrome * adults unable to consent * individuals who are not yet adults (younger than 18 year old) * vulnerable patients (prisoners) * pregnant women

* patient with non-active graft * any significant side effect with previous covid-19 vaccination * within 28 days of bnt162b2 vaccine completion * already received more than and equal to three doses of covid-19 vaccination * previously received covid-19 vaccine other than bnt162b2 vaccine * previously received monoclonal antibody treatment that are specifically directed against the spike protein for severe acute respiratory syndrome (sars) coronavirus 2 (cov)-2 such as mab, bamlanivimab, etesevimab, casirivimab, imdevimab, sotrovimab and/or any combination. * thrombocytopenia (if less than 50,000 per microliter 30 days prior vaccination) * history of capillary leak syndrome * adults unable to consent * individuals who are not yet adults (younger than 18 year old) * vulnerable patients (prisoners) * pregnant women

patient with non-active graft any significant side effect with previous covid-19 vaccination within 28 days of bnt162b2 vaccine completion already received more than and equal to three doses of covid-19 vaccination previously received covid-19 vaccine other than bnt162b2 vaccine previously received monoclonal antibody treatment that are specifically directed against the spike protein for severe acute respiratory syndrome (sars) coronavirus 2 (cov)-2 such as mab, bamlanivimab, etesevimab, casirivimab, imdevimab, sotrovimab and/or any combination. thrombocytopenia (if less than 50,000 per microliter 30 days prior vaccination) history of capillary leak syndrome adults unable to consent individuals who are not yet adults (younger than 18 year old) vulnerable patients (prisoners) pregnant women

patient with non-active graft any significant side effect with previous covid-19 vaccination within 28 days of bnt162b2 vaccine completion already received more than and equal to three doses of covid-19 vaccination previously received covid-19 vaccine other than bnt162b2 vaccine previously received monoclonal antibody treatment that are specifically directed against the spike protein for severe acute respiratory syndrome (sars) coronavirus 2 (cov)-2 such as mab, bamlanivimab, etesevimab, casirivimab, imdevimab, sotrovimab and/or any combination. thrombocytopenia (if less than 50,000 per microliter 30 days prior vaccination) history of capillary leak syndrome adults unable to consent individuals who are not yet adults (younger than 18 year old) vulnerable patients (prisoners) pregnant women

patient with non-active graft any significant side effect with previous covid-19 vaccination within 28 days of bnt162b2 vaccine completion already received more than and equal to three doses of covid-19 vaccination previously received covid-19 vaccine other than bnt162b2 vaccine previously received monoclonal antibody treatment that are specifically directed against the spike protein for sars-cov-2 such as mab, bamlanivimab, etesevimab, casirivimab, imdevimab, sotrovimab and/or any combination. thrombocytopenia (if less than 50,000 per microliter 30 days prior vaccination) history of capillary leak syndrome adults unable to consent individuals who are not yet adults (younger than 18 year old) vulnerable patients (prisoners) pregnant women

patient with non-active graft any significant side effect with previous covid-19 vaccination within 28 days of bnt162b2 vaccine completion already received more than and equal to three doses of covid-19 vaccination previously received covid-19 vaccine other than bnt162b2 vaccine previously received monoclonal antibody treatment that are specifically directed against the spike protein for sars-cov-2 such as mab, bamlanivimab, etesevimab, casirivimab, imdevimab, sotrovimab and/or any combination. thrombocytopenia (if less than 50,000 per microliter 30 days prior vaccination) history of capillary leak syndrome adults unable to consent individuals who are not yet adults (younger than 18 year old) vulnerable patients (prisoners) pregnant women

- patient with non-active graft - any significant side effect with previous covid-19 vaccination - within 28 days of bnt162b2 vaccine completion - already received more than and equal to three doses of covid-19 vaccination - previously received covid-19 vaccine other than bnt162b2 vaccine - previously received monoclonal antibody treatment - history of chronic thrombocytopenia - history of capillary leak syndrome - adults unable to consent - individuals who are not yet adults (younger than 18 year old) - vulnerable patients (prisoners) - pregnant women

- patient with non-active graft - any significant side effect with previous covid-19 vaccination - within 28 days of bnt162b2 vaccine completion - already received more than and equal to three doses of covid-19 vaccination - previously received covid-19 vaccine other than bnt162b2 vaccine - previously received monoclonal antibody treatment - history of chronic thrombocytopenia - history of capillary leak syndrome - adults unable to consent - individuals who are not yet adults (younger than 18 year old) - vulnerable patients (prisoners) - pregnant women

- patient with non-active graft - any significant side effect with previous covid-19 vaccination - within 28 days of bnt162b2 vaccine completion - already received more than and equal to three doses of covid-19 vaccination - previously received covid-19 vaccine other than bnt162b2 vaccine - previous history of lab confirmed sars-cov-2 infection - history of chronic thrombocytopenia - history of capillary leak syndrome - adults unable to consent - individuals who are not yet adults (younger than 18 year old) - vulnerable patients (prisoners) - pregnant women

- patient with non-active graft - any significant side effect with previous covid-19 vaccination - within 28 days of bnt162b2 vaccine completion - already received more than and equal to three doses of covid-19 vaccination - previously received covid-19 vaccine other than bnt162b2 vaccine - previous history of lab confirmed sars-cov-2 infection - history of chronic thrombocytopenia - history of capillary leak syndrome - adults unable to consent - individuals who are not yet adults (younger than 18 year old) - vulnerable patients (prisoners) - pregnant women